TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCON Stock Price Chart Interactive Chart >
TCON Price/Volume Stats
| Current price | $1.65 | 52-week high | $2.90 |
| Prev. close | $1.55 | 52-week low | $1.10 |
| Day low | $1.53 | Volume | 39,500 |
| Day high | $1.67 | Avg. volume | 72,607 |
| 50-day MA | $1.62 | Dividend yield | N/A |
| 200-day MA | $1.67 | Market Cap | 39.31M |
TRACON Pharmaceuticals, Inc. (TCON) Company Bio
Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.
Latest TCON News From Around the Web
Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.
Tracon (TCON) Moves to Buy: Rationale Behind the UpgradeTracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call TranscriptTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. . During today’s call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, […] |
Q4 2022 TRACON Pharmaceuticals Inc Earnings CallQ4 2022 TRACON Pharmaceuticals Inc Earnings Call |
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateSAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 P |
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In add |
TCON Price Returns
| 1-mo | -2.37% |
| 3-mo | 26.44% |
| 6-mo | -7.30% |
| 1-year | -42.31% |
| 3-year | 42.24% |
| 5-year | -93.40% |
| YTD | 10.74% |
| 2022 | -46.21% |
| 2021 | -76.32% |
| 2020 | 400.00% |
| 2019 | -62.86% |
| 2018 | -81.19% |
Loading social stream, please wait...